Skip to main content
爱舍伦 logo

爱舍伦 — Investor Relations & Filings

Ticker · 920050 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 30 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920050

About 爱舍伦

http://www.excellentmedical.cn/

Ascen Medical specializes in the development, manufacturing, and distribution of medical consumables and equipment, with a primary focus on respiratory care, anesthesia, and emergency medicine. The company's product portfolio includes a wide range of airway management solutions such as laryngeal mask airways, endotracheal tubes, breathing circuits, and resuscitation bags. Ascen Medical emphasizes clinical safety and efficiency, adhering to international quality management standards to ensure product reliability. By integrating advanced manufacturing technologies with clinical insights, the company provides essential tools for healthcare professionals in critical care and surgical environments. Its commitment to innovation and quality has established it as a provider of medical solutions for global healthcare markets.

Recent filings

Filing Released Lang Actions
东吴证券股份有限公司关于江苏爱舍伦医疗科技集团股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsoring institution (东吴证券股份有限公司) regarding the use of part of the idle raised funds by 江苏爱舍伦医疗科技集团股份有限公司 for cash management. It includes specifics about the fundraising, usage, investment products, risk control, and approvals by the board and audit committee. The document is not a full financial report but rather a regulatory compliance and verification statement related to the use of raised funds. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy statement. It is a regulatory compliance filing related to fundraising and fund usage, fitting best under Regulatory Filings (RNS). The document length is 4122 characters, which is relatively short and focused on compliance and verification rather than a full report or announcement of a report publication.
2026-03-26 Chinese
东吴证券股份有限公司关于江苏爱舍伦医疗科技集团股份有限公司使用自有资金支付募投项目所需资金并以募集资金等额置换的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor (东吴证券股份有限公司) regarding the use of self-owned funds to pay for investment project personnel expenses by 江苏爱舍伦医疗科技集团股份有限公司 and the equivalent replacement with raised funds. It references regulatory approvals, fundraising details, and compliance with Beijing Stock Exchange rules. The document includes audit committee and board meeting approvals and the sponsor's verification opinion. It is not a full financial report but a regulatory compliance and verification statement related to fundraising and fund usage. The document length is 4234 characters, which is relatively short but contains substantive content about fundraising and fund management verification, not just an announcement or certification. This fits best under Capital/Financing Update (CAP) as it deals with fundraising usage and compliance verification rather than an annual report, audit report, or regulatory filing. Therefore, the classification is CAP with high confidence.
2026-03-26 Chinese
容诚会计师事务所（特殊普通合伙）关于江苏爱舍伦医疗科技集团股份有限公司以自筹资金预先投入募集资金投资项目及支付发行费用的鉴证报告
Audit Report / Information Classification · 85% confidence The document is a standalone verification (assurance) report (“鉴证报告”) issued by an independent accounting firm on the company’s use of self-raised funds, together with a “专项说明” on pre-injection of funds and replacement with raised proceeds. It is not a full annual or quarterly financial report, but a special audit/assurance engagement under the CSRC’s fundraising rules. This matches the definition of an Audit Report / Information (AR). FY 2026
2026-03-26 Chinese
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Jiangsu Aishilun Medical Technology Group Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects and paid issuance expenses. It details the fundraising amount, approval by the board and audit committee, and compliance with regulatory rules. The document is not a full financial report but a specific update on capital usage related to fundraising and project investment. It includes detailed financial figures about the fundraising and fund allocation but is primarily an announcement about capital management and fund replacement. This fits the definition of a Capital/Financing Update (CAP) rather than a full Annual Report, Interim Report, or Regulatory Filing. The document length is 3232 characters, which is substantial but focused on capital usage rather than comprehensive financial statements or audit reports.
2026-03-26 Chinese
关于使用自有资金支付募投项目人员费用并以募集资金等额置换的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Aishilun Medical Technology Group Co., Ltd. regarding the use of self-owned funds to pay personnel expenses for a fundraising investment project and the subsequent replacement of these funds with raised capital. It details the approval process by the board and audit committee, references regulatory approvals from the China Securities Regulatory Commission, and discusses compliance with listing rules and fundraising management regulations. The document is a formal disclosure about the management and use of raised funds, not a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or presentation. It is a regulatory announcement about capital use and compliance with fundraising rules, fitting best under Regulatory Filings (RNS). The document length is 3563 characters, which is relatively short and focused on a specific capital management issue rather than a full report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-03-26 Chinese
第二届董事会第十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 19th meeting of the 2nd Board of Directors of Jiangsu Aisheren Medical Technology Group Co., Ltd. It includes meeting details, voting results, and descriptions of various proposals related to the use of raised funds and internal financial management. The document is not a full financial report, audit report, or earnings release. It is not a shareholder meeting material or voting result announcement but rather a formal disclosure of board meeting decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is 3088 characters, which is consistent with a detailed board meeting resolution announcement rather than a full report or brief notice.
2026-03-26 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.